Recent reports of foreign substances in COVID-19 vaccines have raised public concern about the safety of the vaccines, emphasizing the need for a thorough understanding of the vaccine development and distribution process.
The recent public discourse regarding foreign substances reported in COVID-19 vaccines has intensified concerns among citizens about the vaccines' safety. To fully grasp the implications of these reports, it is crucial to examine the entire process from vaccine research, production, distribution, to administration. The first point to note is whether the vaccines with reported foreign substances were actually administered. In the reported 1,285 cases of foreign substance notifications, the vials containing these substances were immediately isolated and stored according to guidelines, and they were not used for vaccinations. Thus, the number of reports does not indicate that problematic vaccines were administered, but rather reflects an effective management system that successfully filtered out unsuitable products. If the management system were inadequate, reports of such incidents might not have occurred, making it difficult to ascertain the specific occurrence numbers. The existence of detailed reporting data, although appearing alarming, could actually serve as evidence that the management system is functioning properly.
It is also important to examine the nature of the reported foreign substances. Of the total notifications, rubber stopper fragments comprised 835 cases (65%), which is related to the specific characteristics of the distribution and usage of COVID-19 vaccines. These vaccines undergo complex handling processes involving ultra-cold frozen distribution, thawing, dilution, and multi-dose administrations. The design of the vaccine necessitates multiple penetrations of the same vial with a syringe, which can lead to the incorporation of minute rubber stopper fragments. This phenomenon is recognized internationally as a physical characteristic inherent to multi-dose injectables and is specified with allowable limits in clinical literature and by the United States Pharmacopeia (USP). Furthermore, the indicated silicon dioxide is widely used in the medical field and is present in the environment. Exposure to minor amounts does not pose clinically significant health risks and does not impact the balance of benefits and risks presented by the vaccine. Calling for the suspension of the entire administration of vaccines from the same production lot based solely on foreign substance reports that arise from usage characteristics exceeds the bounds of scientific justification.
